Mitochondrial-derived peptide MOTS3 regulates metabolism and cell survival
View Patent ↗MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.
1. A method of treating obesity and/or fatty liver, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an isolated polypeptide or a pharmaceutically acceptable salt thereof comprising SEQ ID NO:1.
2. The method of claim 1 , wherein the subject is a human.
3. The method of claim 1 , wherein said pharmaceutical composition is formulated for unit dosage administration, wherein said isolated polypeptide is dosed from about 0.001 to about 1000 mg per day.
4. The method of claim 1 , wherein said pharmaceutical composition is formulated for unit dosage administration, wherein said isolated polypeptide is dosed from about 0.01 to about 500 mg per day.
5. The method of claim 1 , wherein said pharmaceutical composition is formulated for unit dosage administration, wherein said isolated polypeptide is dosed from about 0.5 to about 100 mg per day.
6. The method of claim 1 , wherein said pharmaceutical composition is formulated as a sterile injectable solution.
7. The method of claim 1 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
8. A method of modulating body weight in a subject in need thereof, the method comprising the step of administering to the subject a pharmaceutical composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a pharmaceutically acceptable salt thereof, in an amount effective to modulate body weight.
9. The method of claim 8 , wherein the subject is overweight and the composition is administered in an amount effective to reduce body weight.